article

Expert view: Where are you seeing changes in the flow cytometry market?

Posted: 10 September 2020 | | No comments yet

We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.

As an example, in the field of oncology, the focus has shifted to a novel class of biologics and cell therapies that modulate immune cell function. This change in therapeutic approach and model complexity requires tools that assess multiple cell parameters to better understand the cellular mechanisms or synergistic effects of combinatorial drug treatments earlier in the discovery process. Furthermore, severe constraints on essential primary cells drive the desire to miniaturise assays and compress analysis workflows.











    To read this expert view in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Sartorius

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend